Suppress the proliferation process of glioblastoma by breaking off the tumor - microenvironment interaction by CRIPSR -mediated technology

Abstract

Glioblastoma is a notorious malignant tumor and traits in cancer provide strong drug resistance. Current Traditional clinical treatments include chemotherapy and surgery, had been proved that showed insufficient effect towards glioblastoma, leading to the requirement of new therapy ------ CRISPR mediated technology therapy application. CRISPR is prior options for gene therapy drug design and using gene-editing principle from the molecular level. Scientists research evaluated the CRIPSR gene therapy had ability in editing related functions of glioblastomas and inducing an immune response by blocking the metabolic activity of cancer cells to achieve anti-cancer effects. We discussed the recent identified potential CRISPR gene therapy targeting sites in glioblastoma gene therapy, including clinical traits and in vivo experiments verified the value in future clinical treatment applications. We also discussed the relationship between the target sites of the glioblastoma genome and the traits they related with. Targeting the angiogenesis regulator factors leads to suppression of glioblastoma proliferation and inhibit the tumor growth. Mediated the tumor micro environment by enhancing antigen present process and reduce glioblastoma interaction with immune cells, could up regulated the anti-tumor immune response. The is also a possibility of combining immune therapy and CRIPSR gene editing therapy together by Car-T therapy. We also discuss the potential delivery method for CRISPR gene-editing therapy, compare the AAV virus method and nanocapsule for assist the edited gene reach the target sties and avoid off-target rate. The CRISPR therapy could be the mainstay in glioblastoma treatment by directly target the glioblastoma metabolism to inhibit tumor proliferation, and could increase survival rate in child glioblastoma treatment as the heterogeneity of glioblastoma is high.